Hikma Pharmaceuticals Plc Total Voting Rights (3125H)
02 Dicembre 2020 - 04:00PM
UK Regulatory
TIDMHIK
RNS Number : 3125H
Hikma Pharmaceuticals Plc
02 December 2020
Hikma Pharmaceuticals PLC
(the Company)
Total Voting Rights and Capital
LONDON, 2 December 2020 - In accordance with the UK Financial
Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals
PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that, in accordance with the Disclosure
Guidance and Transparency Rules ('the Rules'), we notify the market
of the following:
As at 30 November 2020, the issued share capital of the Company
comprised of 230,498,947 ordinary shares with voting rights. This
figure excludes 12,833,233 Shares held in treasury.
The figure of 230,498,947 may be used by shareholders (and
others with notification obligations) as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREADAAEAFEFFA
(END) Dow Jones Newswires
December 02, 2020 10:00 ET (15:00 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024